The Antibody Engine With Abpro's Chan Brothers

Source: Bioprocess Online

In an industry that takes new business naming conventions to etymological extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric, and liver, and ophthalmologic indications DME and wet AMD. With a scientific advisory board led by Bob Langer, Ph.D. of Moderna fame and a new partnership with global powerhouse Celltrion worth a potential $1.75 billion, the company's on the move. On this episode of the Business of Biotech, the Chan brothers take us behind the scenes of Abpro's progress.

Subscribe to the NEW Business of Biotech newsletter for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at!